Skip to main content
. 2018 Apr 9;5(1):57–73. doi: 10.1007/s40744-018-0108-4

Table 2.

Base case results

Treatment Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
Conventional therapy (reference) 107,138 6.93 – – –
Golimumab 146,908 9.00 39,770 2.06 19,280
Adalimumab 148,247 9.02 41,110 2.08 19,737
Certolizumab pegol 154,233 9.45 47,095 2.52 18,710
Etanercept 142,933 8.72 35,795 1.78 20,089

ICER Incremental cost-effectiveness ratio, QALY Quality-adjusted life-year